Bolt Biotherapeutics Net Income 2011-2024 | BOLT

Net income is a financial indicator that reflects the remaining amount of funds after deducting all expenses and taxes from the total income of a company for a certain period of time. It is one of the key indicators of financial stability and success of a business.

Net income is defined as the difference between the net assets (assets minus liabilities) at the beginning of a period and net assets at the end of the period, excluding owners' contributions and distributions during the period.^[1]

It is the result of a company's operations and reflects its efficiency in resource management, expense control, and revenue generation. It includes all operational income and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial indicators.

The calculation of net income includes the deduction of all necessary expenses, such as employee salaries, rent, utilities, taxes, and other mandatory payments. After deducting all these expenses from the total income, the remainder is considered the company's net profit.

It is an important indicator of a company's financial condition as it reflects its ability to generate profit and manage its finances. High net income indicates business success, competitiveness, and efficiency in resource utilization. It also allows the company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

Net income serves as the basis for calculating other financial indicators such as sales profitability, asset profitability, or capital profitability. It is also used to evaluate management efficiency and make decisions about further company development.

Annual Net Income Bolt Biotherapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-69.2 M	-88.1 M	-98.6 M	-	-30.5 M	-11.6 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-11.6 M	-98.6 M	-59.6 M

Quarterly Net Income Bolt Biotherapeutics

2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-15.2 M	-21.2 M	-10.8 M	-	-16.3 M	-18.1 M	-17 M	-	-21.8 M	-22.7 M	-23.7 M	-	-23.4 M	-23.6 M	-24.5 M	-	-10 M	-11.1 M	-8.63 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-8.63 M	-24.5 M	-17.8 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.